Sight Sciences' TearCare Treatment for Dry Eye Disease to Generate Cost Savings Versus Existing Prescribed Medications-February 2024-www.financetom.com

Sight Sciences' TearCare Treatment for Dry Eye Disease to Generate Cost Savings Versus Existing Prescribed Medications

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Sight Sciences' TearCare Treatment for Dry Eye Disease to Generate Cost Savings Versus Existing Prescribed Medications

Dec 19, 2024 3:10 PM

05:48 PM EST, 12/19/2024 (MT Newswires) -- Sight Sciences ( SGHT ) said late Thursday the increased adoption of its TearCare technology to treat patients with dry eye disease associated with meibomian gland dysfunction in the US is projected to yield "meaningful" cost savings based on the results of a budget impact analysis.

The analysis compared the financial impact of TearCare adoption with that of commonly prescribed dry eye medications, the company said.

A 20% increase in market share of TearCare compared to prescription dry eye medications would generate annual savings estimated at $36.87 per member in a hypothetical health plan covering one million people, the company added.

Previous page： This sustainable jewellery brand is luring some women away from gold Next page： SJVN secures 200-MW wind power project at ₹3.24 per unit

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

This sustainable jewellery brand is luring some women away from gold

Oct 30, 2023

Aulerth's offerings range from ₹5,000 to as high as ₹2.8 lakh. Are women willing to spend this much on jewellery made from scrap? Founder and CEO Vivek Ramabhadran definitely believes so. Aulerth produces couture-inspired pieces in association with designers like JJ Valaya, Suneet Varma, among others. It has reported 33% repeat customers in the past year and expects a spike to 40% soon.

SJVN secures 200-MW wind power project at ₹3.24 per unit

Nov 16, 2023

Projected to generate 482 million units in its inaugural year post-commissioning, the cumulative energy generation over a 25-year span is anticipated to reach 12,050 million units. Shares of SJVN Ltd ended at ₹75.17, down by ₹0.50, or 0.66%, on the BSE.

Tata Power Renewable Energy wins 200-MW project in collaboration with SJVN

Nov 28, 2023

The firm and dispatchable renewable energy (FDRE) project, designed with a hybrid of solar, wind, and battery storage, is aimed at providing a stable and dispatchable energy supply during peak hours. Shares of Tata Power Company Ltd ended at ₹270.75, up by ₹12.60, or 4.88%, on the BSE.

Suzlon's S144–3 MW wind turbines get big boost from Indian government

Nov 15, 2023

Th Suzlon wind turbines received the RLMM (Revised List of Models & Manufacturers) listing from the Ministry of New and Renewable Energy, marking an important milestone for the successful commercialisation of the product. Shares of Suzlon Energy Ltd ended at ₹40.49, up by ₹1.85, or 4.79%, on the BSE.